Publications 2022 Aggarwal, A. et al. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia. Nature microbiology 7. Akbil, B. et al. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. Journal of clinical immunology 42. Arora, P. et al. SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. Cell reports 39. Arora, P. et al. No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2. Cellular & molecular immunology 19. Arora, P. et al. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies. Cell host & microbe 30. Chen, H. et al. Detection and functional resolution of soluble immune complexes by an FcγR reporter cell panel. EMBO Mol Med 14. Demichev, V. et al. A proteomic survival predictor for COVID-19 patients in intensive care. PLOS Digit Health 1. Dombret, S., Skapenko, A. & Schulze-Koops, H. Reactive arthritis after SARS-CoV-2 infection. RMD open 8. Dulovic, A. et al. Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. Frontiers in immunology 13. Ercanoglu, M. S. et al. No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults. iScience 25. Freise, N. F. et al. Convalescent plasma treatment for SARS-CoV-2 infected high-risk patients: a matched pair analysis to the LEOSS cohort. Scientific reports 12. Gliga, S. et al. Rapid selection of sotrovimab escape variants in SARS-CoV-2 Omicron infected immunocompromised patients. Clinical infectious diseases. Gruell, H. et al. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell host & microbe 30. Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nature medicine 28. Gruell, H. et al. Antibody-mediated neutralization of SARS-CoV-2. Immunity 55. Habermann, E. et al. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD open 8. Hirsch, C. et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database of Systematic Reviews 6. Hoffmann, M. et al. Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy. mBio 13. Kantauskaite, M. et al. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. American journal of transplantation 22. Kolb, P., Giese, S., Voll, R. E., Hengel, H. & Falcone, V. Immune complexes as culprits of immunopathology in severe COVID-19. Medical microbiology and immunology. Kreuzberger, N. et al. Immunity after COVID-19 vaccination in people with higher risk of compromised immune status: a scoping review. Cochrane Database of Systematic Reviews 8. Li, Q. et al. Immune response in COVID-19: what is next? Cell death and differentiation 29. Liu, Z. et al. Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19. Frontiers in immunology 13. Malin, J. J. et al. SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma. Blood advances 6. Meyer-Arndt, L. et al. Cutting Edge: Serum but Not Mucosal Antibody Responses Are Associated with Pre-Existing SARS-CoV-2 Spike Cross-Reactive CD4+ T Cells following BNT162b2 Vaccination in the Elderly. Journal of immunology 208. Momsen Reincke, S. et al. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Science 375. Peter, L. et al. Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. Molecular therapy. Methods & clinical development 25. Schultze, J. L., Büttner, M. & Becker, M. Swarm immunology: harnessing blockchain technology and artificial intelligence in human immunology. Nature reviews - Immunology 22. Schulz, S. R. et al. Augmented Neutralization of SARS-CoV-2 Omicron Variant by Boost Vaccination and Monoclonal Antibodies. European journal of immunology 52. Schwarz, T. et al. Preserved T cell responses to SARS-CoV-2 in anti-CD20 treated multiple sclerosis. Multiple Sclerosis Journal 28. Theobald, S. J. et al. Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARS‐CoV‐2 mRNA vaccination. EMBO Mol Med 14. Tober-Lau, P. et al. Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. Emerging infectious diseases 28. Vanshylla, K. et al. Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. The Lancet Infectious Diseases 22. Wang, Z. et al. Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens. The Journal of experimental medicine 219. Weber, S. et al. CMV seropositivity is a potential novel risk factor for severe COVID-19 in non-geriatric patients. PloS one 17. 2021 Arora, P. et al. Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. Cellular & molecular immunology 18. Arora, P., Pöhlmann, S. & Hoffmann, M. Mutation D614G increases SARS-CoV-2 transmission. Signal transduction and targeted therapy 6. Arora, P. et al. B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination. Cell reports 37. Augustin, M. et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. The Lancet regional health. Europe 6. Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature medicine 27. Bošnjak, B. et al. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents. Frontiers in immunology 12. Burnett, D. L. et al. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. Immunity 54. Demichev, V. et al. A time-resolved proteomic and prognostic map of COVID-19. Cell Systems 12. Eberhardt, K. A. et al. Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG. Microorganisms 9. Fischer, D. S. et al. Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping'. Nature communications 12. Gaitzsch, E. et al. COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. HemaSphere 5. Georg, P. et al. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. Cell 185. Gieselmann, L. et al. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Nature protocols 16. Gornyk, D. et al. SARS-CoV-2-Seroprävalenz in Deutschland: Eine bevölkerungsbezogene sequenzielle Studie in sieben Regionen. Dtsch Arztebl Int 118. Groß, R. et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine 75. Halwe, S. et al. Intranasal administration of a monoclonal neutralizing antibody protects mice against SARS-CoV-2 infection. Viruses 2021. Hempel, T. et al. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. Chem. Sci. 12. Hennig, V. et al. Increased risk of chronic fatigue and hair loss following COVID-19 in individuals with hypohidrotic ectodermal dysplasia. Orphanet journal of rare diseases 16. Hillus, D. et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. The Lancet Respiratory Medicine 9. Hoff, N.-P. et al. Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction. European journal of medical research 26. Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell reports 36. Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184. Hoffmann, M. et al. SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell reports 35. Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185. Jones, T. C. et al. Estimating infectiousness throughout SARS-CoV-2 infection course. Science 373. Kreuzberger, N. et al. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. The Cochrane database of systematic reviews 9. Kreuzberger, N. et al. Persistence of immunoglobulin G after natural infection with SARS-CoV-2. Cochrane Database of Systematic Reviews 3. Loyal, L. et al. Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science 374. Mahoney, M. et al. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proceedings of the National Academy of Sciences of the United States of America 118. Mühlemann, B. et al. Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalised COVID-19 patients - results from a prospective observational study. Clinical microbiology and infection 27. Oestreich, M., Chen, D., Schultze, J. L., Fritz, M. & Becker, M. Privacy considerations for sharing genomics data. EXCLI journal 20. Peter, A. S. et al. A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. European journal of immunology 52. Renn, M. et al. Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. Pharmacology & Therapeutics 228. Ruhl, L. et al. Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks. Signal transduction and targeted therapy 6. Schmidt, K. G. et al. SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses. Frontiers in immunology 12. Schrezenmeier, E. et al. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in immunology 12. Schuh, W. et al. A surrogate cell-based SARS-CoV-2 spike blocking assay. European journal of immunology 51. Schulz, S. R. et al. Augmented Neutralization of SARS-CoV-2 Omicron Variant by Boost Vaccination and Monoclonal Antibodies. European journal of immunology 52. Schwarz, T. et al. SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. Frontiers in immunology 12. Schwarz, T. et al. Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerging infectious diseases 27. Theobald, S. J. et al. Long–lived macrophage reprogramming drives spike protein–mediated inflammasome activation in COVID–19. EMBO Mol Med 13. Thibeault, C. et al. Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. Infection 49. Tober-Lau, P. et al. Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February-March 2021. Emerging infectious diseases 27. Tober-Lau, P. et al. Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. The Lancet Respiratory Medicine 9. Trimpert, J. et al. Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. Viruses 13. Vanshylla, K. et al. Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans. Cell host & microbe 29. Vanshylla, K. et al. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell host & microbe 30. Vesper, N. et al. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants. Frontiers in immunology 12. Wagner, K. I. et al. Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection. Cell reports 38. Warnat-Herresthal S, Schultze H, Shastry KL, et al. Swarm Learning for decentralized and confidential clinical machine learning. Nature 594. Wendisch, D. et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell 184. Witkowski, M. et al. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature 600. 2020 Bacher, P. et al. Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity 53. Preprints Ankerhold, J. et al. Enhanced FcγRIII/CD16 activation by discrete ligands as independent correlates of disease severity in COVID-19 patients (2021). Chen H, Maul-Pavicic A, Holzer M, et al. Immune Complex Solubility and Size Govern Fc-Gamma Receptor Responses: A Scalable Cell-Based Reporter System Reincke, S. M. et al. SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. Rodiah, I. et al. Age-specific Contribution of Contacts to Transmission of SARS-CoV-2 in Germany.